Crispr Therapeutics (NASDAQ:CRSP) released its earnings results on Wednesday. The company reported $0.51 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $1.19, Zacks reports. The business had revenue of $77.00 million during the quarter, compared to analyst estimates of $39.08 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The company’s revenue for the quarter was up 76900.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.92) earnings per share.
Shares of CRSP opened at $58.12 on Friday. Crispr Therapeutics has a 12-month low of $30.53 and a 12-month high of $74.00. The firm has a market capitalization of $3.15 billion, a P/E ratio of -126.35 and a beta of 3.25. The firm has a 50-day moving average price of $57.85 and a 200 day moving average price of $53.01. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares in the company, valued at $465,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. 21.40% of the stock is currently owned by company insiders.
CRSP has been the topic of several research reports. Piper Jaffray Companies reissued a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research note on Monday, December 16th. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday. BidaskClub lowered shares of Crispr Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Finally, Canaccord Genuity raised their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and an average target price of $78.29.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Bond
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.